388P Subgroup analysis of patients (pts) with HER2-low metastatic breast cancer (mBC) with brain metastases (BMs) at baseline from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC)
Junji Tsurutani(Showa University Hospital), William Jacot(Institut de Recherche en Cancérologie de Montpellier), Toshinari Yamashita(Kanagawa Prefectural Hospital Organization), Farhan Riaz(Stanford Medicine), Rinat Yerushalmi(Tel Aviv University), S-A. Im(Seoul National University Hospital), Naoki Niikura(Tokai University), U. Halser-Strub(Kantonsspital St. Gallen), Javier Cortés, A-K. Wennstig(Sundsvall Municipality), Y.S. Chae(Kyungpook National University Hospital), X. Wang(Zhejiang Cancer Hospital), Wěi Li(Jilin University), H. Simon(Centre Hospitalier Régional Universitaire de Brest), Giovanna Masci(IRCCS Humanitas Research Hospital), Emiliano Tamburini, C. Orbegoso Aguilar, Kristen M. Tecson(Daiichi Sankyo (United States)), Lotus Yung(Daiichi Sankyo (United States)), Shanu Modi(Memorial Sloan Kettering Cancer Center)
Cited by 16Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis